Author

I. Kovalenko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

C. A. Lyssiotis· 2 shared C. J. Halbrook· 2 shared D. M. Kremer· 2 shared H. C. Crawford· 2 shared H.-J. Lee· 2 shared A. Biankin· 1 shared A. C. Kimmelman· 1 shared A. Myers· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. A. Lyssiotis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tissue of Origin Dictates GOT1 Dependence and Confers Synthetic Lethality to Radiotherapy

B. S. Nelson, L. Lin, D. M. Kremer, C. M. Sousa, C. Cotta-Ramusino, A. Myers, J. Ramos, T. Gao, I. Kovalenko, K. Wilder-Romans, J. Dresser, M. Davis, H.-J. Lee, Z. C. Nwosu, S. Campit, , C. A. Lyssiotis

The paper shows that pancreatic ductal adenocarcinoma (PDA) is more dependent on GOT1 than colorectal cancer (CRC) and that GOT1 inhibition synergizes with radiotherapy to inhibit PDA growth.

bioRxiv · Jul 25, 2019Cancer Biology

Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

C. J. Halbrook, C. Pontious, H.-J. Lee, I. Kovalenko, Y. Zhang, L. Lapienyte, S. Dreyer, D. M. Kremer, P. Sajjakulnukit, L. Zhang, B. Nelson, H. Hong, S. Kemp, D. Chang, A. Biankin, , C. A. Lyssiotis

This study shows macrophages in pancreatic cancer release pyrimidines that inhibit gemcitabine therapy by competing with the drug for uptake and metabolism, and reducing macrophage burden improves treatment response.

bioRxiv · Nov 5, 2018Cancer Biology